Adherium

Adherium (ASX.ADR) is a global leader in digital health technologies which address sub-optimal medication use in chronic disease. Its Smartinhaler™ platform has been independently proven to improve medication adherence and health outcomes for patients with chronic respiratory disease. Adherium has the broadest range of "smart"​ devices for respiratory medications globally. Adherium Smartinhalers attach to prescription inhalers to provide reminders and monitoring of inhaler usage. The SmartinhalerLive platform uses wireless communications technology to provide real time data collection and reporting from the Company's Smartinhalers. Smartinhaler™ technology has been independently shown to: - Increase adherence to preventative medication by 180% in children and 59% in adults; - Reduce severe exacerbations in adults by 60%; and - Contribute to significant improvements in quality of life for people with chronic asthma. The Smartinhaler™ platform has so far been used in more than 40 projects (clinical, device validation or other). The Company has received FDA 510(k) notifications for clearance to market and CE Marks for its devices and software, which allows it to sell these devices into international markets.